Welcome







Posters and Abstracts

Complete Listing

The following is the complete list of posters and abstracts accepted for presentation at Maui Derm Connect 2020. Be sure to watch the September 13 panel discussion of selected highlights from the submissions.

  • 10735 – Baraliakos
    Secukinumab Improves Clinical and Imaging Outcomes in Patients With Psoriatic Arthritis and Axial Manifestations With Inadequate Response to NSAIDs: Week 52 Results From the MAXIMISE Trial
    Xenofon Baraliakos, Laure Gossec, Effie Pournara, S?awomir Jeka, Ricardo Blanco, Salvatore D’Angelo, Georg Schett, Barbara Schulz, Michael Rissler, Kriti Nagar, Chiara Perella, Laura C. Coates
    Uploaded: 2020-08-26

    Abstract

    Poster

  • 10742 – Bertucci
    Lip enhancement, naturalness, and subject and partner satisfaction after HARK treatment
    Vince Bertucci, MD; Nowell Solish, MD; and Andreas Nikolis, MD
    Uploaded: 2020-08-24

    Abstract

    Poster

  • 10751 – Bissonnette
    Efficacy of tapinarof cream by body region in subjects with plaque psoriasis in a phase 2b randomized controlled study
    Robert Bissonnette, Linda Stein Gold, Leon Kircik, Stephen Tyring, Anna Tallman, April Armstrong
    Uploaded: 2020-08-07

    Abstract

    Poster

  • 10714 – Blauvelt
    Tirbanibulin Ointment 1% for Actinic Keratosis (AK): Results From Two Phase 3 Studies with 1-Year Follow-up
    Kempers, Puig, Martin, Fumero, Grada, Cutler, Fang
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10732 – Blauvelt
    Ixekizumab vs. Guselkumab: Direct Comparison of Cumulative Clinical and Quality of Life Benefits Over 24 Weeks of Treatment in Patients With Moderate-to-Severe Plaque Psoriasis
    Andrew Blauvelt, Kim A. Papp, Melinda Gooderham, Neil J. Korman, Ronald Vender, Russel Burge, Baojin Zhu, Gaia Gallo, So Young Park, Hany Elmaraghy, Fangyu Wang, Renata Gontijo Lima, Lisa Renda
    Uploaded: 2020-08-31

    Abstract

    Poster

  • 10719 – Cantrell
    Efficacy and Safety of Tildrakizumab 100 mg for Plaque Psoriasis in Patients Randomized to Treatment Continuation vs Treatment Withdrawal with Retreatment upon Relapse in reSURFACE 1
    Wendy Cantrell, Patricia Lee, Alan M Mendelsohn, Stephen J Rozzo, Wilson Liao
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10718 – Cather
    Rates of Malignancies Through 5 Years of Tildrakizumab Exposure in reSURFACE 1 and reSURFACE 2
    Jennifer Cather, Beatrice Nardone, Alan M Mendelsohn, Stephen J Rozzo, Elizabeth Ergen
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10744 – Del Rosso
    TRIFAROTENE 50 �g/g CREAM: AN EFFECTIVE AND SAFE TREATMENT FOR MODERATE FACIAL AND TRUNCAL ACNE
    James Del Rosso, DO; Jerry Tan, MD; Jonathan Weiss, MD; Linda Stein Gold, MD; Fran Cook-Bolden, MD; Lawrence Eichenfield, MD; Emil Tanghetti, MD; Michael Graeber, MD; Alessandra Ali� Saenz, MD; Faiz Ahmad, PhD
    Uploaded: 2020-08-21

    Abstract

    Poster

  • 10712 – Dosik
    Phase I Study to Evaluate the Sensitizing Potential of Tirbanibulin Ointment 1%, a Novel Treatment for Actinic Keratosis (AK), in Healthy Subjects
    Cuter, Fang
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10713 – Dosik
    Phase I Study to Evaluate the Potential of Tirbanibulin Ointment 1%, a Novel Treatment for Actinic Keratosis (AK), to Induce a Phototoxicity Skin Reaction in Healthy Subjects
    Cuter, Fang
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10737 – Dummer
    Effect of concomitant medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
    Reinhard Dummer, Michael Migden, Nicholas Squittieri, Li Liu, Alexander Guminski, John Lear
    Uploaded: 2020-08-26

    Abstract

  • 10726 – Emil A Tanghetti, MD
    A New Tazarotene 0.045% Lotion Formulation for Moderate-to-Severe Acne: Efficacy and Safety in Phase 2 and Phase 3 Clinical Trials
    Emil A Tanghetti, MD; William Philip Werschler, MD; Edward Lain, MD, MBA; Ashlie M Caronia, FNP; Eric Guenin, PharmD, PhD, MPH; Susan Harris, MS; Anya Loncaric, MS; Radhakrishnan Pillai, PhD
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10734 – Gil Yosipovitch
    Dupilumab Treatment Results in Rapid Improvement in Itch in Adult and Adolescent Patients With Moderate-to-Severe Atopic Dermatitis (LIBERTY AD SOLO 1 and 2 and ADOL trials)
    Gil Yosipovitch, Chih-ho Hong, Eric L. Simpson, Zhen Chen, Ana Rossi
    Uploaded: 2020-08-31

    Abstract

    Poster

  • 10716 – Gordon
    BMS-986165, an Oral, Selective Tyrosine Kinase 2 (TYK2) Inhibitor: Evaluation of Changes in Laboratory Parameters in Response to Treatment in a Phase 2 Trial in Psoriasis Patients
    Kenneth Gordon, Kim Papp, Melinda Gooderham, Akimichi Morita, Peter Foley, Diamant Tha�i, Sudeep Kundu, Renata Kisa, Lan Wei, Subhashis Banerjee
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10715 – Gottlieb
    BMS-986165, an Oral, Selective TYK2 Inhibitor, in the Treatment of Moderate to Severe Psoriasis as Assessed by the Static Physician�s Global Assessment (sPGA)/Body Surface Area (BSA) Composite Tool (sPGA�BSA), a Clinically Useful Alternative to PASI
    Alice B. Gottlieb, Bruce Strober, Diamant Tha�i, Kenneth Gordon, Sudeep Kundu, Renata Kisa, Lan Wei, Subhashis Banerjee, Joseph F. Merola
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10740 – Kwong
    The Hidden Impact of Molluscum Contagiosum: Survey of Caregivers� Experiences with Diagnosis and Management
    Pearl Kwong, Adelaide Hebert, Collette Utley, Melissa Olivadoti
    Uploaded: 2020-08-25

    Abstract

    Poster

  • 10724 – Lakshi Aldredge, MSN, RN, ANP-BC
    Efficacy of a Fixed Combination Halobetasol Propionate 0.01%/Tazarotene 0.045% Lotion in Females with Psoriasis and Perception of Vehicle Properties
    Lakshi Aldredge, MSN, RN, ANP-BC; Linda Stein Gold, MD; Boni Elewski, MD; Zoe Draelos, MD; TJ Chao, MPAS, PA-C; Abby Jacobson, MS, PA-C
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10721 – Langley
    Efficacy and Safety of Long-Term Tildrakizumab for Plaque Psoriasis: 4-Year Results from reSURFACE 1 and reSURFACE 2
    Richard G Langley, Jeffrey Crowley, Melinda Gooderham, Kim A Papp, Neil J Korman, Lynda Spelman, Atsuyuki Igarashi, Mamitaro Ohtsuki, Aditya K Gupta, Paul Yamauchi, Alan M Mendelsohn, Stephen J Rozzo, Kimberly Eads, Scott Guenthner, M Alan Menter
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10738 – Lear
    Effect of concomitant common cardiovascular medications on efficacy of sonidegib 200 mg daily in patients with locally advanced basal cell carcinoma: Results of the 42-month randomized, double-blind BOLT study
    John Lear, Reinhard Dummer, Alexander Guminski, Nicholas Squittieri, Li Liu, Michael Migden
    Uploaded: 2020-08-26

    Abstract

    Poster

  • 10720 – Lebwohl
    Tildrakizumab Efficacy by Metabolic Syndrome Status in Psoriasis: Post Hoc Analysis of 3-Year Data from the Phase 3 reSURFACE 1 and reSURFACE 2 Studies
    Mark G Lebwohl, Nehal N Mehta, Alice B Gottlieb, Alan M Mendelsohn, Stephen J Rozzo, M Alan Menter
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10750 – Lebwohl
    Tapinarof cream for the treatment of plaque psoriasis: Efficacy and safety by baseline disease characteristics and skin type in a phase 2b randomized study
    Mark Lebwohl, James Del Rosso, Chih-ho Hong, Anna Tallman, Leon Kircik
    Uploaded: 2020-08-07

    Abstract

    Poster

  • 10725 – Leonardi
    Long-Term Efficacy and Safety Profile through 5 Years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis
    Craig Leonardi, Kristian Reich, Lyn Guenther, Melinda Gooderham, Laura Ferris, Ann Leung, Hany Elmaraghy, Heidi Crane, David Shrom, Christopher E. M. Griffiths
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10727 – Leonardi
    Long-term Efficacy and Safety Profile Through 5 Years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Psoriasis
    Craig Leonardi, Kristian Reich, Lyn Guenther, Melinda Gooderham, Laura K. Ferris, Ann Leung, Hany Elmaraghy, Heidi Crane, David Shrom, Christopher E. M. Griffiths
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10730 – Leonardi
    Long-Term Efficacy and Safety Profile through 5 Years of Treatment with Ixekizumab in Patients with Moderate-to-Severe Plaque Psoriasis
    Craig Leonardi, Kristian Reich, Lyn Guenther, Melinda Gooderham, Laura Ferris, Ann Leung, Hany Elmaraghy, Heidi Crane, David Shrom, Christopher E. M. Griffiths
    Uploaded: 2020-08-31

    Abstract

  • 10736 – Magnolo
    Secukinumab Is Highly Efficacious and Has a Favorable Safety Profile in Pediatric Patients With Moderate-to-Severe Plaque Psoriasis
    Nina Magnolo, MD, K�lli Kingo, MD, PhD, Vivian Laquer, MD, John Browning, MD, Deborah Keefe, MD, Rafal Mazur, MD, Prayashi Ghelani, BSc, MSc, Manmath Patekar, MD, LindaAnn Wraith, MBA, Adam Reich, MD, PhD
    Uploaded: 2020-08-26

    Abstract

    Poster

  • 10717 – Mease
    Efficacy and Safety of Tildrakizumab, a High-affinity Anti�interleukin-23p19 Monoclonal Antibody, in Patients with Active Psoriatic Arthritis
    Philip J Mease, Saima Chohan, Ferran J Garc�a Fructuoso, Alice B Gottlieb, Proton Rahman, Siba P Raychaudhuri, Richard C Chou, Alan M Mendelsohn, Stephen J Rozzo, Cynthia Trickett, Melodie Young, Michael E Luggen
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10709 – Moore
    Oral Sarecycline for Moderate to Severe Acne Vulgaris
    Green, Bruce
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10710 – Moore
    Oral Sarecycline for Moderate to Severe Acne Vulgaris
    Green, Bruce
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10722 – Papp
    Early and Maintained Response Levels in Psoriasis Patients Treated with Tildrakizumab
    Kim Papp, Jensen Yeung, Neil Shear, Lorne Albrecht, Charles Lynde, Jingchuan Zhang, Yang Zhao, Alan M Mendelsohn, Melinda Gooderham
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10711 – Pariser
    Safety and Tolerability of Sarecycline for the Treatment of Acne Vulgaris: Results from a Phase III, Multicenter, Open-Label Study and a Phase I Phototoxicity Study
    Green, Lain, Schmitz, Chinigo, McNamee, Berk
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10739 – Pearl Kwong
    The Hidden Impact of Molluscum Contagiosum: Survey of Caregivers� Experiences with Diagnosis and Management
    Pearl Kwong, Adelaide Hebert, Collette Utley, Melissa Olivadoti
    Uploaded: 2020-08-25

    Abstract

    Poster

  • 10733 – Querfeld
    Concomitant Use of Steroids and Chlormethine Gel Among Patients with Mycosis Fungoides-type Cutaneous T-cell Lymphoma (MF-CTCL): A Real-World Evidence Study
    Christiane Querfeld, Gary Binder, Marco Turini, Deval Gor, Christina L. Wassel, Chris Pashos
    Uploaded: 2020-08-31

    Abstract

    Poster

  • 10723 – Rice
    Quality of Life Impact and Awareness of Primary Focal Hyperhidrosis in Children and Adolescents
    Z. P. Rice, L.J. Pieretti, A. Wheeler, J. Payne, K.K. Gillard, T. Devlin, A.A. Hebert
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10745 – Robert
    Characteristics of patients with a complete response treated with dabrafenib plus trametinib combination therapy: Findings from pooled COMBI-d and COMBI-v 5-year analysis
    Caroline Robert, Jean-Jacques Grob, Daniil Stroyakovskiy, Boguslawa Karaszewska, Axel Hauschild, Evgeny Levchenko, Vanna Chiarion Sileni, Jacob Schachter, Claus Garbe, Igor Bondarenko, Paul Nathan, Antoni Ribas, Michael A. Davies, Keith Flaherty, Paul Burgess, Monique Tan, Eduard Gasal, Dirk Schadendorf, Georgina V. Long
    Uploaded: 2020-08-18

    Abstract

    Poster

  • 10743 – Schlessinger
    Subjects are Highly Satisfied with Two Treatments of AbobotulinumtoxinA a Year: Results from a Multi-Center, Year-long, Longitudinal Study
    Joel Schlessinger, MD; Joel L. Cohen, MD; Ava Shamban, MD; Carolyn Jacob, MD; Kian Karimi, MD; Corey Maas, MD
    Uploaded: 2020-08-21

    Abstract

    Poster

  • 10747 – Silverberg
    Use of topical corticosteroids with tralokinumab in adult patients with moderate-to-severe atopic dermatitis: results from the 32-week, Phase 3 ECZTRA 3 trial
    Jonathan I. Silverberg, Andrew E. Pink, Azra Kurbasic, Christina Kurre Olsen, Stephan Weidinger
    Uploaded: 2020-08-07

    Abstract

  • 10748 – Silverberg
    Early changes in patient-relevant endpoints in three tralokinumab pivotal Phase 3 trials (ECZTRA 1?3) in adult patients with moderate-to-severe atopic dermatitis
    Jonathan I. Silverberg, Michael Cork, Andreas Wollenberg, Norito Katoh, Louise Abildgaard Steffensen, Azra Kurbasic, Christina Kurre Olsen, Alexandra Kuznetsova, Marie Louise �sterdal, Andreas Westh Vilsb�ll, Mette Deleuran
    Uploaded: 2020-08-07

    Abstract

  • 10728 – Simpson
    Efficacy and Safety of Baricitinib in Moderate-to-Severe Atopic Dermatitis: Results from a Randomized, Double-Blinded, Placebo-Controlled Phase 3 Clinical Trial (BREEZE-AD5)
    Eric Simpson, Seth Forman, Jonathan Silverberg, Matthew Zirwas, Emanual Maverakis, George Han, Emma Guttman-Yassky, Daniel Marnell, Robert Bissonnette, Jill Waibel, Fabio Nunes, Amy M. DeLozier, Robinette Angle, Katrin Holzwarth, Orin Goldblum, Jinglin Zhong, Kim Papp
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10729 – Simpson
    Rapid and Concurrent Improvements in Signs and Symptoms of Atopic Dermatitis with Baricitinib in Phase 3 Studies
    Eric L. Simpson, Jacob P. Thyssen, Robert Bissonnette, Bochao Jia, Fabio P. Nunes, Marta Casillas, Amy M. DeLozier, Maria Jose Rueda, Jonathan M. Janes, Emma Guttman-Yassky, Kristian Reich, Thomas Bieber
    Uploaded: 2020-09-01

    Abstract

    Poster

  • 10749 – Simpson
    Tralokinumab monotherapy in adult patients with moderate-to-severe atopic dermatitis: regional differences in baseline disease characteristics and prior treatment in the ECZTRA 1 and ECZTRA 2 trials
    Eric Simpson, Thomas Werfel, Thomas Bieber, Louise Abildgaard Steffensen, Alexandra Kuznetsova, Marie Louise �sterdal, Hidehisa Saeki
    Uploaded: 2020-08-07

    Abstract

  • 10731 – Van Voorhees
    Outcomes in Ixekizumab Initiators By Prior Biologic Status in the Corrona� Psoriasis Registry
    Abby S. Van Voorhees, Ryan W. Harrison, Russel Burge, William N. Malatestinic, Baojin Zhu, Bilal Atiya, Mwangi J. Murage, Robert R. McLean, Margaux Crabtree, Jacqueline O�Brien, Benjamin Lockshin
    Uploaded: 2020-08-31

    Abstract

    Poster

  • 10746 – Weidinger
    Tralokinumab improves clinically relevant outcome measures: a post hoc analysis of ECZTRA 3, a randomized clinical trial in patients with moderate-to-severe atopic dermatitis
    Stephan Weidinger, Andrew E. Pink, Juan Francisco Silvestre, Azra Kurbasic, Christina Kurre Olsen, Andreas Westh Vilsb�ll, Marjolein de Bruin Weller
    Uploaded: 2020-08-07

    Abstract

  • 10741 – Weiss
    A Randomized, Controlled, Evaluator-Blinded, Multi-Center Study to Evaluate the Effectiveness and Safety of HARK versus a Control in the Augmentation of Soft Tissue Fullness of the Lip
    Robert Weiss, MD; Kenneth Beer, MD; Sue Ellen Cox, MD; Melanie Palm, MD, MBA; Joely Kaufman-Janette, MD; Ben Bassichis, MD; Brian Biesman, MD; John Joseph, MD
    Uploaded: 2020-08-24

    Abstract

    Poster

Panel Discussion